The Hematologic Malignancy Center offers specialized programs for the treatment of leukemia, lymphoma, histiocytosis, and lymphadenopathy through Dana-Farber/Boston Children's Cancer and Blood Disorders Center, an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children's Hospital. Our center played a key role in refining treatment for childhood leukemia, resulting in today's cure rates of more than 90 percent for pediatric acute lymphoblastic leukemia, and we continue to lead high-impact clinical trials designed to increase cure rates and decrease treatment-related toxicities for long-term survivors.
Conditions We Treat
Specialized Treatment Programs for Hematologic Malignancies
Please visit the Dana-Farber Cancer Institute website to learn more about our Hematologic Malignancy Center, including information about: